Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oracle
ORCL
|
+$881M |
| 2 |
DoorDash
DASH
|
+$403M |
| 3 |
Amgen
AMGN
|
+$403M |
| 4 |
Amazon
AMZN
|
+$282M |
| 5 |
Applied Materials
AMAT
|
+$231M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$592M |
| 2 |
Workday
WDAY
|
+$580M |
| 3 |
United Parcel Service
UPS
|
+$468M |
| 4 |
Apple
AAPL
|
+$438M |
| 5 |
Atlassian
TEAM
|
+$428M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.97% |
| 2 | Healthcare | 19.05% |
| 3 | Consumer Discretionary | 10.13% |
| 4 | Financials | 9.7% |
| 5 | Industrials | 9.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Wayfair
W
$11.8B
| $110M | 0.06% |
1,627,712
+1,316,865
| +424% | +$74.5M |
|
252
S&P Global
SPGI
$124B
| $110M | 0.06% |
258,726
-17,574
| -6% | -$7.62M |
|
|
CHX
253
DELISTED
ChampionX
CHX
| $109M | 0.06% |
3,024,688
-262,735
| -8% | -$7.86M |
|
254
Mirion Technologies
MIR
$3.56B
| $107M | 0.06% |
9,403,114
+3,929
| +0% | +$39.4K |
|
255
PTC Therapeutics
PTCT
$6.18B
| $107M | 0.06% |
3,669,816
+1,057,223
| +40% | +$29.6M |
|
256
Cisco
CSCO
$443B
| $106M | 0.06% |
2,123,140
-3,169,118
| -60% | -$158M |
|
|
ACLX
257
DELISTED
Arcellx
ACLX
| $106M | 0.06% |
1,522,309
-15,901
| -1% | -$1.01M |
|
258
Maximus
MMS
$3.32B
| $105M | 0.06% |
1,254,536
+25,825
| +2% | +$2.12M |
|
259
Western Alliance Bancorporation
WAL
$8.81B
| $104M | 0.06% |
1,617,291
-1,829
| -0.1% | -$112K |
|
260
Donaldson
DCI
$10.7B
| $104M | 0.06% |
1,389,144
-21,115
| -1% | -$1.44M |
|
261
Arista Networks
ANET
$199B
| $103M | 0.06% |
1,420,660
-116,928
| -8% | -$7.89M |
|
262
BridgeBio Pharma
BBIO
$16.4B
| $102M | 0.06% |
3,312,706
+2,169,143
| +190% | +$73.8M |
|
263
4D Molecular Therapeutics
FDMT
$502M
| $102M | 0.06% |
3,197,444
+104,148
| +3% | +$2.66M |
|
264
Regal Rexnord
RRX
$12.5B
| $101M | 0.06% |
560,701
-580,853
| -51% | -$90.5M |
|
265
Regeneron Pharmaceuticals
REGN
$72.9B
| $100M | 0.05% |
103,992
-8,837
| -8% | -$8.4M |
|
266
UBS Group
UBS
$170B
| $100M | 0.05% |
3,247,489
-158,839
| -5% | -$4.69M |
|
267
Advanced Drainage Systems
WMS
$10.6B
| $98.8M | 0.05% |
573,217
-16,886
| -3% | -$2.54M |
|
268
NeoGenomics
NEO
$1.99B
| $98.7M | 0.05% |
6,280,866
-67,747
| -1% | -$1.05M |
|
269
AvalonBay Communities
AVB
$27.5B
| $96.8M | 0.05% |
521,815
+29,953
| +6% | +$5.39M |
|
270
Clarivate
CLVT
$1.37B
| $95.8M | 0.05% |
12,900,281
+139,610
| +1% | +$1.17M |
|
271
Trip.com Group
TCOM
$29B
| $95.5M | 0.05% |
2,175,488
-40,517
| -2% | -$1.65M |
|
272
Shift4
FOUR
$4.45B
| $94.8M | 0.05% |
1,434,890
+255,741
| +22% | +$19.2M |
|
273
Amphenol
APH
$185B
| $94.3M | 0.05% |
1,634,340
+6,180
| +0.4% | +$324K |
|
274
3M
MMM
$91.8B
| $94.2M | 0.05% |
1,062,723
+967,462
| +1,016% | +$80.2M |
|
275
Crinetics Pharmaceuticals
CRNX
$8.88B
| $92.5M | 0.05% |
1,978,172
+1,434,909
| +264% | +$56.1M |
|
Similar funds
Janus Henderson Group's Q1 2024 Portfolio in Review
As of Q1 2024, Janus Henderson Group held 2,613 positions worth $183B, up 9.3% from $168B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Janus Henderson Group's Q1 2024 filing shows 67 new, 1,353 increased, 903 reduced and 85 closed positions. Its largest new stake was CG Oncology: 1,521,432 shares worth $66.8M. The largest sale was Abbott, an estimated $592M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q1 2024 buy was CG Oncology: 1,521,432 shares worth $66.8M.
- Janus Henderson Group added most to Oracle in Q1 2024, an estimated $881M increase.
- Janus Henderson Group's biggest Q1 2024 reduction was Abbott, cutting an estimated $592M.
- Janus Henderson Group fully exited Immunogen Inc in Q1 2024, selling an estimated $327M.
- Janus Henderson Group's ten largest holdings make up 28% of its $183B portfolio in Q1 2024.
- Janus Henderson Group opened 67 new positions and closed 85 in Q1 2024.
- Janus Henderson Group's portfolio value rose 9.3% quarter-over-quarter to $183B.
Based on Janus Henderson Group's 13F filing for Q1 2024, filed 15 May 2024.